Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: The British Columbia Cancer Agency experience

Gynecologic Oncology

Volumn 98, Issue 1, 2005, Pages 54-58

  Tinker, A V ^a   Bhagat, K ^b   Swenerton, K D ^b   Hoskins, P J ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Carboplatin; Cervical carcinoma; Paclitaxel; Recurrent disease; Treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIOSENSITIVITY; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 20444442671     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.03.037     Document Type: Article

References (25)

1. M. Morris, K.R. Brader, C. Levenback, T.W. Burke, E.N. Atkinson, and W.R. Scott Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix J. Clin. Oncol. 16 3 1998 1094 1098
2. T. Thigpen, R.B. Vance, and T. Khansur Carcinoma of the uterine cervix: current status and future directions Semin. Oncol. 21 2 Suppl. 2 1994 43 54 [quiz 55, 58]
3. W.P. McGuire, J.A. Blessing, D. Moore, S.S. Lentz, and G. Photopulos Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study J. Clin. Oncol. 14 3 1996 792 795
4. R.J. Schilder, J.A. Blessing, M. Morgan, C.E. Mangan, and J.S. Rader Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group Gynecol. Oncol. 76 2 2000 204 207
5. M.A. Bookman, J.A. Blessing, P. Hanjani, T.J. Herzog, and W.A. Andersen Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group Gynecol. Oncol. 77 3 2000 446 449
6. G.A. Omura Chemotherapy for cervix cancer Semin. Oncol. 21 1 1994 54 62
7. H.N. Nguyen, and S.R. Nordqvist Chemotherapy of advanced and recurrent cervical carcinoma Semin. Surg. Oncol. 16 3 1999 247 250
8. D.S. Alberts, R. Kronmal, L.H. Baker, D.L. Stock-Novack, E.A. Surwit, and J.G. Boutselis Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group study J. Clin. Oncol. 5 11 1987 1791 1795
9. G.A. Omura, J.A. Blessing, L. Vaccarello, M.L. Berman, D.L. Clarke-Pearson, and D.G. Mutch Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study J. Clin. Oncol. 15 1 1997 165 171
10. J.D. Bloss, J.A. Blessing, B.C. Behrens, R.S. Mannel, J.S. Rader, and A.K. Sood Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study J. Clin. Oncol. 20 7 2002 1832 1837
11. F. Ghaemmaghami, N. Behtash, F. Yarandi, A. Moosavi, M. Modares, and G. Toogeh First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study J. Obstet. Gynaecol. 23 4 2003 422 425
12. M.S. Piver, S.A. Ghamande, G.H. Eltabbakh, and C. O'Neill-Coppola First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix-A phase II study Gynecol. Oncol. 75 3 1999 334 337
13. P.G. Rose, J.A. Blessing, D.M. Gershenson, and R. McGehee Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J. Clin. Oncol. 17 9 1999 2676 2680
14. D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J. Clin. Oncol. 22 15 2004 3113 3119
15. E.C. Grendys, H.J. Long, B.N. Bundy, J. Benda, D.S. McMeekin, and J.I. Sorosky Randomized phase III trial of cisplatin (P) versus cisplatin and topotecan (T) versus methotrexate, vincristine, adriamycin and cisplatin (MVAC) in stage IVB, recurrent or persistent carcinoma of the uterine cervix: a Gynecologic Oncology Group study 10th Biennial Meeting of the International Gynecologic Cancer Society. Edinburgh, Scotland; October 2004
16. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 17 2003 3194 3200
17. A. du Bois, H.J. Luck, W. Meier, V. Mobus, S. Costa, and B. Richter Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group Semin. Oncol. 24 5 Suppl. 15 1997 S15-44 S15-52
18. D.S. Alberts Carboplatin versus cisplatin in ovarian cancer Semin. Oncol. 22 5 Suppl. 12 1995 88 90
19. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J. Natl. Cancer Inst. 92 3 2000 205 216
20. B.J. Monk, H. Huang, and L. Wenzel Quality of life outcomes from a phase III trial of cisplatin versus cisplatin plus topotecan in stage IVB, recurrent or persistent carcinoma of the cervix: results of GOG protocol 179 Gynecol. Oncol. 92 2004 473 [abstract 177]
21. G.R. Weiss, S. Green, E.V. Hannigan, J.G. Boutselis, E.A. Surwit, and D.L. Wallace A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study Gynecol. Oncol. 39 3 1990 332 336
22. K.R. Brader, M. Morris, C. Levenback, L. Levy, K.R. Lucas, and D.M. Gershenson Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design J. Clin. Oncol. 16 5 1998 1879 1884
23. B.J. Monk Management of stage IVB and recurrent cervical cancer International Symposium on Ovarian Cancer and Other Gynecologic Malignancies April 16-18, 2004; New York, NY 2004
24. M. Morris, J.A. Blessing, B.J. Monk, R. McGehee, and D.H. Moore Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J. Clin. Oncol. 22 16 2004 3340 3344
25. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, and S. Costa A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 17 2003 1320 1329